AYTU

Stats

Summary

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.

Market Cap: 16.7 Million

Primary Exchange: NASDAQ

Website:

Shares Outstanding: 5.57 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.0835693015499257

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 982 trading days

From: 2021-03-18 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor
2017-08-29				20.0	1.0	20.0